Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer.
J Int Med Res
; 41(5): 1437-44, 2013 Oct.
Article
en En
| MEDLINE
| ID: mdl-24065453
ABSTRACT
OBJECTIVE:
To investigate the levels of microRNA-210 (miR-210) in the serum of patients with nonsmall-cell lung cancer (NSCLC) and to determine whether there was a correlation with the prognosis of NSCLC patients following cisplatin-based chemotherapy.METHODS:
Quantitative real-time reverse transcription-polymerase chain reaction was used to measure the serum levels of miR-210 in patients with NSCLC and healthy age-matched control subjects. Correlations between serum miR-210 levels and clinicopathological factors and prognosis were investigated.RESULTS:
Serum miR-210 was significantly upregulated in 60 patients with NSCLC compared with 30 healthy control subjects. Higher serum miR-210 levels were significantly correlated with the clinical stage and the presence of regional lymph node metastasis in patients with NSCLC. Serum miR-210 levels in patients that achieved a partial response following cisplatin-based chemotherapy were significantly lower than in patients with stable or progressive disease, and were similar to those in healthy control subjects.CONCLUSIONS:
These findings suggest that serum miR-210 levels might be a novel diagnostic and prognostic marker of NSCLC.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Regulación Neoplásica de la Expresión Génica
/
Carcinoma de Pulmón de Células no Pequeñas
/
MicroARNs
/
Neoplasias Pulmonares
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
J Int Med Res
Año:
2013
Tipo del documento:
Article